• Competing with precision: incentives for developing predictive biomarker tests 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;06/2022, Working paper, 2022-03)
      We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework ...
    • Diffusion of pharmaceuticals : cross-country evidence of anti-TNF drugs 

      Brekke, Kurt Richard; Dalen, Dag Morten; Holmås, Tor Helge (Discussion paper;7/2013, Working paper, 2013-03)
      This paper studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information on ...
    • The Price of Cost-effectiveness Thresholds 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;04/2023, Working paper, 2023)
      Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform decisions about access and reimbursement. We study how CE thresholds imposed by a health plan for granting reimbursement ...
    • Taking the competitor’s pill: when combination therapies enter pharmaceutical markets 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (DP SAM;19/2023, Working paper, 2023-11-22)
      We study the competitive effects of combination therapies in pharmaceutical markets, which crucially hinge on the additional therapeutic value of combinatory use of drugs and the therapeutic substitutability with the most ...